IOVA Slumps, MSON On Watch, ALRN To Report Data In Q4

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Iovance Biotherapeutics Inc. (IOVA)

Lost 24.78% to close Thursday's (Sep.6) trading at $12.75.

News: Investors were not impressed with the updated data related to the Company's phase II trial of LN-144 TIL in patients with advanced melanoma presented at the H.C. Wainwright Global Investor Conference.

2. Dicerna Pharmaceuticals Inc. (DRNA)

Lost 18.11% to close Thursday's trading at $13.02.

News: The Company announced the commencement of a proposed underwritten registered public offering of 6.15 million shares of its common stock.

Recent event:

On September 5, the Company announced encouraging preliminary proof-of-concept data from its ongoing PHYOX Phase 1 clinical trial evaluating DCR-PHXC in the treatment of primary hyperoxaluria.

Near-term Catalysts:

-- Detailed data readout of the PHYOX Trial is anticipated in Q4 2018. -- Initiate a multi-dose Phase 2/3 study of DCR-PHXC in the treatment of primary hyperoxaluria in the first quarter of 2019. -- File regulatory clearances for human clinical trials in New Zealand and Australia for DCR-HBVS, in development for the treatment of chronic HBV, during the fourth quarter of 2018.

3. Innovate Biopharmaceuticals Inc. (INNT)

Lost 15.10% to close Thursday's trading at $6.52.

News: The Company hosted an event for members of the financial community on Thursday, September 6, 2018, in New York.

Pipeline:

-- INN-202 entering Phase 3 for the treatment of celiac disease (CeD) with Fast Track designation -- INN-217 entering Phase 1/2 for nonalcoholic steatohepatitis (NASH) alone and/or in combination with other agents -- INN-289 entering Phase 1 for a subset of Crohn's disease (CD) -- INN-108 entering Phase 2 for inflammatory bowel disorders, mild to moderate ulcerative colitis (UC), and a GI orphan disease in a convenient liquid formulation -- INN-329 entering Phase 3 for magnetic resonance cholangiopancreatography (MRCP).

4. Ritter Pharmaceuticals Inc. (RTTR)

Lost 13.55% to close Thursday's trading at $1.85.

News: No news

Clinical Trials:

The first phase III study of RP-G28 for lactose intolerance is underway. Two confirmatory clinical trials are expected for NDA filing.

5. Misonix Inc. (MSON)

Lost 13.22% to close Thursday's trading at $15.75.

News: The Company reported financial results for the fiscal 2018 fourth quarter and year ended June 30, 2018.

Net loss from continuing operations for the year ended June 30, 2018 widened to $7.61 million or $0.87 per share from $1.68 million or $0.22 per share in the prior year. Total revenue for fiscal 2018 jumped to $36.67 million from $27.26 million in fiscal 2017.

Looking ahead, the Company expects double-digit top-line growth to continue in fiscal 2019.

6. Aileron Therapeutics Inc. (ALRN)

Lost 11.26% to close Thursday's trading at $3.39.

News: The Company announced the appointment of Manuel Aivado as CEO.

Pipeline:

The Company's lead product candidate is ALRN-6924.

Multiple clinical studies of ALRN-6924 are underway, including a Phase 1 All-comers trial in advanced solid tumors or lymphomas, a Phase 2a trial in peripheral T-cell lymphoma (PTCL), a Phase 1 trial in acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS) as a monotherapy, and a Phase 1b trial in AML/MDS in combination with cytosine arabinoside (Ara-C).

Near-term Catalysts:

-- Additional interim data from the Phase 2a trial of ALRN-6924 for the treatment of patients with peripheral T-cell lymphoma are expected to be reported in the fourth quarter of 2018. -- Interim data from Phase 1 and 1b open-label, multi-center clinical trials of ALRN-6924 as a monotherapy and in combination with cytosine arabinoside (Ara-C) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are expected in the fourth quarter of this year.